(Newser) -
A drug designed to protect cancer patients' bones also renders breast cancer relapses less likely, a new study says. Funded in part by the drug's maker, Novartis, researchers found that even two injections of Zometa a year cut tumor recurrence by 35% in more than 1,800 pre-menopausal women.
More »
